Teva terminates Ajovy at Phase 3 in episodic cluster headache

pharmafile | April 24, 2019 | News story | Research and Development Teva, ajovy, headache, pharma 

Israeli pharmaceutical firm Teva has announced its intention to terminate further development of its calcitonin gene-related peptide (CGRP) inhibitor Ajovy (fremanezumab) in the treatment of episodic cluster headaches after it became apparent that the drug is unlikely to meet its primary endpoint at Phase 3.

Conclusions drawn from a pre-specified futility analysis of the Phase 3 ENFORCE study indicated that Ajovy would not adequately improve mean change from baseline in the weekly average number of cluster headache attacks during the 4-week treatment period, so the drugmaker has decided to discontinue the trial.

Despite the decision, Teva made clear that it would still pursue other applications of Ajovy, particularly in the treatment of post-traumatic headache, which is currently being evaluated at Phase 2.

“We’d like to thank the patients and investigators for their immense contributions to this study,” remarked Dr Tushar Shah, Senior Vice President, Head of Global Specialty Clinical Development at Teva. “Despite these results, we are continuing to evaluate if fremanezumab treatment can provide clinical benefits in additional diseases where anti-calcitonin gene-related peptide (CGRP) therapy may play a role in its pathophysiology.”

Matt Fellows

Related Content

Pfizer sign

Delayed Pfizer vaccine dose gives 3.5 times more immunity, study shows

The Pfizer-BioNTech COVID-19 vaccine is around three and a half times more effective when dosed …

Amgen flag

AstraZeneca and Amgen asthma drug shows positive results in Phase III trial

AstraZeneca and Amgen’s new tezepelumab drug for the treatment of severe asthma has shown superiority …

India report record number of COVID deaths as bodies drift down Ganges

India yesterday reported the country’s highest COVID-19 death total for a single day, with 4,205 …

Latest content